OP134 Pan-Canadian Oncology Drug Review Decisions And Access To Anticancer Treatments In Canada
Introduction: The Canadian Agency for Drugs and Technologies in Health (CADTH) pan-Canadian Oncology Drug Review (pCODR) plays an important role in public reimbursement decision-making for oncology drugs in Canada. This research studies the relation of positive pCODR decisions to new cancer treatmen...
Published in: | International Journal of Technology Assessment in Health Care |
---|---|
Main Authors: | , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Cambridge University Press (CUP)
2018
|
Subjects: | |
Online Access: | http://dx.doi.org/10.1017/s0266462318001526 https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0266462318001526 |
id |
crcambridgeupr:10.1017/s0266462318001526 |
---|---|
record_format |
openpolar |
spelling |
crcambridgeupr:10.1017/s0266462318001526 2024-03-03T08:46:45+00:00 OP134 Pan-Canadian Oncology Drug Review Decisions And Access To Anticancer Treatments In Canada Singh, Ambrish Hussain, Salman 2018 http://dx.doi.org/10.1017/s0266462318001526 https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0266462318001526 en eng Cambridge University Press (CUP) https://www.cambridge.org/core/terms International Journal of Technology Assessment in Health Care volume 34, issue S1, page 50-50 ISSN 0266-4623 1471-6348 Health Policy journal-article 2018 crcambridgeupr https://doi.org/10.1017/s0266462318001526 2024-02-08T08:36:58Z Introduction: The Canadian Agency for Drugs and Technologies in Health (CADTH) pan-Canadian Oncology Drug Review (pCODR) plays an important role in public reimbursement decision-making for oncology drugs in Canada. This research studies the relation of positive pCODR decisions to new cancer treatment and their subsequent inclusion in Canada's public drug plans. Methods: We studied all oncology drugs that received an approval from Health Canada and were reviewed by the pCODR from inception till 26th Sep, 2017. The data was obtained from CADTH and Health Canada. Data such as indication, submission type and date, recommendation date, final recommendation, and subsequent provincial funding status was extracted and analyzed. Impact was evaluated by analyzing the percentage of drug submissions with assessment outcome (positive recommendation rate and conditional recommendation rate) and time taken for the final decision (recommendation gap). The percentage of drugs included in public formulary after positive recommendation by pCODR (coverage rate) and the gap in days from positive recommendation to subsequent coverage in provinces (coverage gap) was also assessed. Results: Among 119 drugs reviewed by pCODR, the positive recommendation rate was eight percent. Nine applications comprising seven drugs for six indications received positive recommendations, and genitourinary treatments received maximum positive recommendations. The conditional recommendation rate was 52 percent; 62 applications of 45 drugs for 46 indications received conditional recommendation. Lymphoma and myeloma treatments received maximum conditional recommendations. The average recommendation gap for positive and conditional recommendations was 180 and 172 days, respectively. The coverage rate for drugs with positive recommendation was 100 percent for all provinces except 89 percent for Newfoundland and Labrador, and 67 percent for Prince Edward Island. Among the provinces, British Columbia had a maximum of 433 days and Saskatchewan has the minimum of ... Article in Journal/Newspaper Newfoundland Prince Edward Island Cambridge University Press Newfoundland Canada British Columbia ENVELOPE(-125.003,-125.003,54.000,54.000) International Journal of Technology Assessment in Health Care 34 S1 50 50 |
institution |
Open Polar |
collection |
Cambridge University Press |
op_collection_id |
crcambridgeupr |
language |
English |
topic |
Health Policy |
spellingShingle |
Health Policy Singh, Ambrish Hussain, Salman OP134 Pan-Canadian Oncology Drug Review Decisions And Access To Anticancer Treatments In Canada |
topic_facet |
Health Policy |
description |
Introduction: The Canadian Agency for Drugs and Technologies in Health (CADTH) pan-Canadian Oncology Drug Review (pCODR) plays an important role in public reimbursement decision-making for oncology drugs in Canada. This research studies the relation of positive pCODR decisions to new cancer treatment and their subsequent inclusion in Canada's public drug plans. Methods: We studied all oncology drugs that received an approval from Health Canada and were reviewed by the pCODR from inception till 26th Sep, 2017. The data was obtained from CADTH and Health Canada. Data such as indication, submission type and date, recommendation date, final recommendation, and subsequent provincial funding status was extracted and analyzed. Impact was evaluated by analyzing the percentage of drug submissions with assessment outcome (positive recommendation rate and conditional recommendation rate) and time taken for the final decision (recommendation gap). The percentage of drugs included in public formulary after positive recommendation by pCODR (coverage rate) and the gap in days from positive recommendation to subsequent coverage in provinces (coverage gap) was also assessed. Results: Among 119 drugs reviewed by pCODR, the positive recommendation rate was eight percent. Nine applications comprising seven drugs for six indications received positive recommendations, and genitourinary treatments received maximum positive recommendations. The conditional recommendation rate was 52 percent; 62 applications of 45 drugs for 46 indications received conditional recommendation. Lymphoma and myeloma treatments received maximum conditional recommendations. The average recommendation gap for positive and conditional recommendations was 180 and 172 days, respectively. The coverage rate for drugs with positive recommendation was 100 percent for all provinces except 89 percent for Newfoundland and Labrador, and 67 percent for Prince Edward Island. Among the provinces, British Columbia had a maximum of 433 days and Saskatchewan has the minimum of ... |
format |
Article in Journal/Newspaper |
author |
Singh, Ambrish Hussain, Salman |
author_facet |
Singh, Ambrish Hussain, Salman |
author_sort |
Singh, Ambrish |
title |
OP134 Pan-Canadian Oncology Drug Review Decisions And Access To Anticancer Treatments In Canada |
title_short |
OP134 Pan-Canadian Oncology Drug Review Decisions And Access To Anticancer Treatments In Canada |
title_full |
OP134 Pan-Canadian Oncology Drug Review Decisions And Access To Anticancer Treatments In Canada |
title_fullStr |
OP134 Pan-Canadian Oncology Drug Review Decisions And Access To Anticancer Treatments In Canada |
title_full_unstemmed |
OP134 Pan-Canadian Oncology Drug Review Decisions And Access To Anticancer Treatments In Canada |
title_sort |
op134 pan-canadian oncology drug review decisions and access to anticancer treatments in canada |
publisher |
Cambridge University Press (CUP) |
publishDate |
2018 |
url |
http://dx.doi.org/10.1017/s0266462318001526 https://www.cambridge.org/core/services/aop-cambridge-core/content/view/S0266462318001526 |
long_lat |
ENVELOPE(-125.003,-125.003,54.000,54.000) |
geographic |
Newfoundland Canada British Columbia |
geographic_facet |
Newfoundland Canada British Columbia |
genre |
Newfoundland Prince Edward Island |
genre_facet |
Newfoundland Prince Edward Island |
op_source |
International Journal of Technology Assessment in Health Care volume 34, issue S1, page 50-50 ISSN 0266-4623 1471-6348 |
op_rights |
https://www.cambridge.org/core/terms |
op_doi |
https://doi.org/10.1017/s0266462318001526 |
container_title |
International Journal of Technology Assessment in Health Care |
container_volume |
34 |
container_issue |
S1 |
container_start_page |
50 |
op_container_end_page |
50 |
_version_ |
1792502807053467648 |